Antibody and B cell responses to SARS-CoV-2 infection and vaccination

Cell Host Microbe. 2021 Jul 14;29(7):1063-1075. doi: 10.1016/j.chom.2021.06.009. Epub 2021 Jun 17.

Abstract

Antibodies, and the B cell and plasma cell populations responsible for their production, are key components of the human immune system's response to SARS-CoV-2, which has caused the coronavirus disease 2019 (COVID-19) pandemic. Here, we review findings addressing the nature of antibody responses against SARS-CoV-2 and their role in protecting from infection or modulating COVID-19 disease severity. In just over a year, much has been learned, and replicated in independent studies, about human immune responses to this pathogen, contributing to the development of effective vaccines. Nevertheless, important questions remain about the duration and effectiveness of antibody responses, differences between immunity derived from infection compared to vaccination, the cellular basis for serological findings, and the extent to which viral variants will escape from current immunity.

Publication types

  • Research Support, N.I.H., Extramural
  • Review

MeSH terms

  • Antibodies, Viral / immunology*
  • B-Lymphocytes / immunology*
  • COVID-19 / immunology*
  • COVID-19 Vaccines / therapeutic use*
  • Cross Reactions
  • Humans
  • Immunity
  • Immunity, Mucosal
  • Pandemics
  • SARS-CoV-2 / immunology*
  • Spike Glycoprotein, Coronavirus / chemistry
  • Spike Glycoprotein, Coronavirus / immunology
  • Vaccination*

Substances

  • Antibodies, Viral
  • COVID-19 Vaccines
  • Spike Glycoprotein, Coronavirus
  • spike protein, SARS-CoV-2